Home » Stocks » Biocept

Biocept, Inc. (BIOC)

Stock Price: $1.02 USD 0.02 (2.00%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed
After-hours: $0.96 -0.06 (-5.88%) Aug 12, 7:59 PM

Stock Price Chart

Key Info

Market Cap 133.72M
Revenue (ttm) 5.95M
Net Income (ttm) -27.56M
Shares Out 131.10M
EPS (ttm) -0.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $1.02
Previous Close $1.00
Change ($) 0.02
Change (%) 2.00%
Day's Open 1.08
Day's Range 1.00 - 1.08
Day's Volume 13,443,263
52-Week Range 0.21 - 1.30

More Stats

Market Cap 133.72M
Enterprise Value 114.54M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 131.10M
Float 122.08M
EPS (basic) -0.86
EPS (diluted) -0.74
FCF / Share -0.30
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.93M
Short Ratio 0.30
Short % of Float 4.12%
Beta 0.75
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 22.47
PB Ratio 6.58
Revenue 5.95M
Operating Income -23.38M
Net Income -27.56M
Free Cash Flow -23.80M
Net Cash 19.18M
Net Cash / Share 0.15
Gross Margin -91.57%
Operating Margin -392.96%
Profit Margin -463.60%
FCF Margin -399.97%
ROA -56.54%
ROE -150.02%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$1.53*
(50.00% upside)
Low
1.00
Current: $1.02
High
2.06
Target: 1.53
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue5.533.255.073.220.610.130.130.11
Revenue Growth70.09%-35.87%57.26%428.46%357.15%-0.62%22.83%-
Gross Profit-5.45-6.80-4.28-3.70-3.99-2.04-2.20-1.09
Operating Income-23.06-24.26-21.17-18.03-16.41-13.87-7.94-10.50
Net Income-25.14-24.57-21.61-18.40-16.95-15.87-9.23-12.26
Shares Outstanding20.662.800.920.320.180.04--
Earnings Per Share-1.22-9.01-23.58-57.63-92.11-357.34-4,572.50-6,879.46
Operating Cash Flow-23.05-22.36-19.65-15.70-15.15-14.58-6.20-8.61
Capital Expenditures-0.74-0.15-1.40-0.45-0.17-0.39--0.01
Free Cash Flow-23.78-22.50-21.05-16.15-15.32-14.97-6.20-8.62
Cash & Equivalents9.303.422.154.618.825.360.070.19
Total Debt2.541.632.794.174.674.897.4022.63
Net Cash / Debt6.761.80-0.640.434.150.47-7.33-22.44
Assets17.738.757.387.5810.596.571.331.47
Liabilities6.535.716.086.926.896.7913.7928.85
Book Value11.203.041.300.663.69-0.22-12.46-27.38
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Biocept, Inc.
Country United States
Employees 88
CEO Michael W. Nall

Stock Information

Ticker Symbol BIOC
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Laboratories & Research
Unique Identifier NASDAQ: BIOC
IPO Date February 5, 2014

Description

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. The company's Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from ctDNA. In addition, it offers laboratory services to medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians to determine the treatment plan for their patients, as well as to pharmaceutical and biopharmaceutical companies developing drug candidate therapies to treat cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.